Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Aptus Pharma
Quarter-by-quarter operating performance
Financials of Aptus Pharma
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 13.90 | 17.81 | 24.56 | 46.57 |
| Expenses + | 13.28 | 16.27 | 19.71 | 39.12 |
| Operating Profit | 0.62 | 1.54 | 4.85 | 7.45 |
| OPM % | 4.46% | 8.65% | 19.75% | 16.00% |
| Other Income + | 0.00 | 0.03 | 0.08 | 0.13 |
| Interest | 0.14 | 0.24 | 0.47 | 0.80 |
| Depreciation | 0.18 | 0.21 | 0.27 | 0.41 |
| Profit before tax | 0.30 | 1.12 | 4.19 | 6.37 |
| Tax % | 33.33% | 28.57% | 26.01% | 27.47% |
| Net Profit + | 0.19 | 0.80 | 3.10 | 4.62 |
| EPS in Rs | 2.38 | 10.00 | 2.48 | 2.69 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Aptus Pharma
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.30 | 0.30 | 5.00 | 6.86 |
| Reserves | 0.67 | 1.47 | 1.97 | 16.49 |
| Borrowings + | 2.22 | 5.31 | 10.35 | 7.18 |
| Other Liabilities + | 3.02 | 2.95 | 4.60 | 13.00 |
| Total Liabilities | 6.21 | 10.03 | 21.92 | 43.53 |
| Fixed Assets + | 0.52 | 0.63 | 0.99 | 2.77 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets + | 5.69 | 9.40 | 20.93 | 40.76 |
| Total Assets | 6.21 | 10.03 | 21.92 | 43.53 |
Financials of Aptus Pharma
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -0.18 | -2.17 | -1.84 | -6.86 |
| Cash from Investing Activity + | -0.35 | -0.30 | -0.54 | -6.37 |
| Cash from Financing Activity + | 0.81 | 2.86 | 6.68 | 9.04 |
| Net Cash Flow | 0.28 | 0.38 | 4.30 | -4.19 |
| Free Cash Flow | -0.53 | -2.50 | -2.46 | -9.05 |
| CFO/OP | -10% | -119% | -15% | -76% |
Financials of Aptus Pharma
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 63.02 | 68.66 | 83.82 | 147.03 |
| Inventory Days | 176.00 | 183.57 | 285.06 | 231.78 |
| Days Payable | 104.07 | 72.25 | 52.89 | 139.20 |
| Cash Conversion Cycle | 134.95 | 179.97 | 315.98 | 239.61 |
| Working Capital Days | 51.99 | 67.02 | 36.41 | 116.78 |
| ROCE % | 26.48% | 38.20% | 29.97% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…